One drug attacks tumor cells directly, the other treats the immune system by taking the brakes off T cell response. Together, they put half of the patients with relapsed follicular lymphoma into complete remission in a phase II clinical trial at the University of Texas MD Anderson Cancer Center.
Fuente : http://www.eurekalert.org/pub_releases/2013-12/uot...
Fuente : http://www.eurekalert.org/pub_releases/2013-12/uot...